|  | 
| Mechanismtissue factor modulators | 
|  | 
|  | 
|  | 
|  | 
| Drug Highest PhasePhase 3 | 
| First Approval Ctry. / Loc.- | 
| First Approval Date- | 
| Target- | 
| Mechanism- | 
|  | 
|  | 
|  | 
| Inactive Indication- | 
| Drug Highest PhasePreclinical | 
| First Approval Ctry. / Loc.- | 
| First Approval Date- | 
 / Unknown statusPhase 2/3 A Phase II/III, Randomized, Controlled, Single Blind Study to Evaluate the Haemostatic Efficacy and Safety of Topically Applied TT-173 in Patients Undergoing Knee Arthroplasty
The purpose of this study is to determine the haemostatic efficacy of TT-173, reducing the total blood loss associated with the total knee arthroplasty.
A Phase II Randomized, Controlled, Single Blind Study to Evaluate the Haemostatic Efficacy and Safety of TT-173 Applied in the Donor Site of Patients Undergoing Skin Graft
The purpose of this study is to determine the haemostatic efficacy of TT-173, reducing the bleeding time in the donor site of skin grafting.
A Phase 1, Randomized, Open, Controlled, Comparative Safety, Tolerability and Efficacy Study of TT-173 in Healthy Volunteers After Tooth Extraction
The purpose of this study is to evaluate the safety, tolerability and efficacy of TT-173 in healthy volunteers after tooth extraction.
100 Clinical Results associated with Thrombotargets Corp.
0  Patents (Medical) associated with Thrombotargets Corp.
100 Deals associated with Thrombotargets Corp.
100 Translational Medicine associated with Thrombotargets Corp.